Key result
Novel biomarkers including miRNA and H-FABP aid in diagnosing acute myocardial infarction and ACS.
Answers are grounded in this paper and cite their sources.
Preoperative assessment of cardiovascular risk is essential when it comes to extensive noncardiac surgery procedures. Therefore, accurate and timely diagnosis of myocyte damage is vital. In modern medical practice it is believed that the so-called "multimarker" approach is the most appropriate and most accurate, but new research points out that there are novel biomarkers which could be used independently. Studies that evaluate miRNA, H-FABP, and MR-PAMP give encouraging results. When it comes to miRNA clinical studies show high statistical significance, especially in the case of acute myocardial infarction (P = 0.001). Statistical significance of P = 0.007 was found in acute coronary syndrome, when H-FABP was measured. Biochemical marker MR-PAMP showed statistical significance of P < 0.0001 in most clinical studies.
No takes yet. Share an insight, caveat, or question.
Janković et al. (2015) conducted a review in Cardiovascular risk in noncardiac surgery, acute myocardial infarction, and acute coronary syndrome. Novel cardiac biomarkers (miRNA, H-FABP, MR-PAMP) vs. Multimarker approach was evaluated on Diagnosis of myocyte damage, acute myocardial infarction, and acute coronary syndrome (p=<0.0001). Novel cardiac biomarkers showed statistical significance for diagnosing myocyte damage, including miRNA in AMI, H-FABP in ACS, and MR-PAMP.
Synapse has enriched 10 related papers. Consider them for comparative context: